Literature DB >> 30100106

Preserved anabolic threshold and capacity as estimated by a novel stable tracer approach suggests no anabolic resistance or increased requirements in weight stable COPD patients.

Renate Jonker1, Nicolaas E P Deutz1, Gerdien C Ligthart-Melis1, Anthony J Zachria2, Eugene A Veley3, Rajesh Harrykissoon2, Mariëlle P K J Engelen4.   

Abstract

BACKGROUND & AIMS: Assessing the ability to respond anabolic to dietary protein intake during illness provides important insight in the capacity of lean body mass maintenance. We applied a newly developed stable tracer approach to assess in one session in patients with chronic obstructive pulmonary disease (COPD) and healthy older adults both the minimal amount of protein intake to obtain protein anabolism (anabolic threshold) and the efficiency of dietary protein to promote protein anabolism (anabolic capacity).
METHODS: We studied 12 clinically and weight stable patients with moderate to very severe COPD (mean ± SE forced expiratory volume in 1 s: 36 ± 3% of predicted) and 10 healthy age-matched older adults. At 2-h intervals and in consecutive order, all participants consumed a mixture of 0.0, 0.04, 0.10 and 0.30 g hydrolyzed casein protein×kg ffm-1×2 h-1 and carbohydrates (2:1). We assessed whole body protein synthesis (PS), breakdown (PB), net PS (PS-PB) and net protein balance (phenylalanine (PHE) intake - PHE to tyrosine (TYR) hydroxylation) by IV primed and continuous infusion of L-[ring-2H5]PHE and L-[13C9,15N]-TYR. Anabolic threshold (net protein balance = 0) and capacity (slope) were determined on an individual basis from the assumed linear relationship between protein intake and net protein balance.
RESULTS: We confirmed a linear relationship between protein intake and net protein balance for all participants (R2 range: 0.9988-1.0, p ≤ 0.0006). On average, the anabolic threshold and anabolic capacity were comparable between the groups (anabolic threshold COPD vs. healthy: 3.82 ± 0.31 vs. 4.20 ± 0.36 μmol PHE × kg ffm-1 × hr-1; anabolic capacity COPD vs. healthy: 0.952 ± 0.007 and 0.954 ± 0.004). At protein intake around the anabolic threshold (0.04 and 0.10 g protein×kg ffm-1×2 h-1), the increase in net PS resulted mainly from PB reduction (p < 0.0001) whereas at a higher protein intake (0.30 g protein×kg ffm-1×2 h-1) PS was also stimulated (p < 0.0001).
CONCLUSIONS: The preserved anabolic threshold and capacity in clinically and weight stable COPD patients suggests no disease related anabolic resistance and/or increased protein requirements. TRIAL REGISTRY: ClinicalTrials.gov; No. NCT01734473; URL: www.clinicaltrials.gov.
Copyright © 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  COPD; Casein; Protein anabolism; Protein requirements; Protein threshold

Year:  2018        PMID: 30100106      PMCID: PMC6355392          DOI: 10.1016/j.clnu.2018.07.018

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  40 in total

1.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

Review 2.  Appropriate protein provision in critical illness: a systematic and narrative review.

Authors:  L John Hoffer; Bruce R Bistrian
Journal:  Am J Clin Nutr       Date:  2012-07-18       Impact factor: 7.045

3.  Muscle protein synthesis response to exercise training in obese, older men and women.

Authors:  Gordon I Smith; Dennis T Villareal; David R Sinacore; Krupa Shah; Bettina Mittendorfer
Journal:  Med Sci Sports Exerc       Date:  2012-07       Impact factor: 5.411

4.  The Physical Activity Scale for the Elderly (PASE): development and evaluation.

Authors:  R A Washburn; K W Smith; A M Jette; C A Janney
Journal:  J Clin Epidemiol       Date:  1993-02       Impact factor: 6.437

5.  Nutritional assessment and therapy in COPD: a European Respiratory Society statement.

Authors:  Annemie M Schols; Ivone M Ferreira; Frits M Franssen; Harry R Gosker; Wim Janssens; Maurizio Muscaritoli; Christophe Pison; Maureen Rutten-van Mölken; Frode Slinde; Michael C Steiner; Ruzena Tkacova; Sally J Singh
Journal:  Eur Respir J       Date:  2014-09-18       Impact factor: 16.671

6.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

7.  Mechanisms of altered protein turnover in chronic diseases: a review of human kinetic studies.

Authors:  Gianni Biolo; Raffaella Antonione; Rocco Barazzoni; Michela Zanetti; Gianfranco Guarnieri
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2003-01       Impact factor: 4.294

8.  Corticosteroids contribute to muscle weakness in chronic airflow obstruction.

Authors:  M Decramer; L M Lacquet; R Fagard; P Rogiers
Journal:  Am J Respir Crit Care Med       Date:  1994-07       Impact factor: 21.405

9.  Recent advances in determining protein and amino acid requirements in humans.

Authors:  Rajavel Elango; Ronald O Ball; Paul B Pencharz
Journal:  Br J Nutr       Date:  2012-08       Impact factor: 3.718

Review 10.  Role of specific dietary amino acids in clinical conditions.

Authors:  Renate Jonker; Mariëlle P K J Engelen; Nicolaas E P Deutz
Journal:  Br J Nutr       Date:  2012-08       Impact factor: 3.718

View more
  3 in total

1.  ω-3 polyunsaturated fatty acid supplementation improves postabsorptive and prandial protein metabolism in patients with chronic obstructive pulmonary disease: a randomized clinical trial.

Authors:  Mariëlle P K J Engelen; Renate Jonker; Hooriya Sulaiman; Helena L Fisk; Philip C Calder; Nicolaas E P Deutz
Journal:  Am J Clin Nutr       Date:  2022-09-02       Impact factor: 8.472

2.  Intestinal function is impaired in patients with Chronic Obstructive Pulmonary Disease.

Authors:  Sarah K Kirschner; Nicolaas E P Deutz; Renate Jonker; Steven W M Olde Damink; Rajesh I Harrykissoon; Anthony J Zachria; Srinivasan Dasarathy; Mariëlle P K J Engelen
Journal:  Clin Nutr       Date:  2020-10-10       Impact factor: 7.324

3.  Activated whole-body arginine pathway in high-active mice.

Authors:  Jorge Z Granados; Gabriella A M Ten Have; Ayland C Letsinger; John J Thaden; Marielle P K J Engelen; J Timothy Lightfoot; Nicolaas E P Deutz
Journal:  PLoS One       Date:  2020-06-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.